[Clinical and hemodynamic characteristics of ischemic heart disease in patients with deficient body mass]. / Klinicheskie i gemodinamicheskie osobennosti ishemicheskoi bolezni serdtsa u lits s nedostatochnoi massoi tela.

AIM: To elucidate clinical and hemodynamic characteristics of patients with ischemic heart disease and low body mass. MATERIAL: Patients with stable angina (n=162) divided into 3 groups according to body mass index (below 25, 25-27 kg/m2 and above 27 kg/m2). RESULTS: Patients with low body mass index compared with those with intermediate values had worse clinical (arrhythmias, derangements of conduction, recurrent myocardial infarctions, cases with heart failure), hemodynamic (lower stroke volume and cardiac index, higher total peripheral resistance), and cardiometric (lower ejection fraction, larger diastolic volumes, greater relative myocardial mass) characteristics. CONCLUSION: These findings constitute a pathophysiological substrate for increased risk of death in patients with ischemic heart disease and deficient body mass.

[Prevention of myocardial damage during hemolytic anemia by antioxidants]. / Preduprezhdenie povrezhdeniia miokarda pri gemoliticheskoi anemii s pomoshch'iu antioksidantov.

Structural and functional disorders of the heart muscle were studied in rats with phenylhydrazine-induced chronic hemolytic anemia, as was the possibility of their prevention with anti-oxidant Ionol, a lipid peroxidation inhibitor. Hemolytic anemia was shown to produce myocardial contractural damage, myocytolysis, fatty infiltration, small-focal necrosis, the so-called central lumpy decay phenomenon. These lesions are accompanied with depressed cardiac contractility. Although anti-oxidant Ionol, a lipid peroxidation inhibitor, administered to animals simultaneously with phenylhydrazine, does not prevent hemolytic anemia, it reduces twofold the number of lesion foci in the heart muscle and limits significantly the depression of cardiac contractility.